1. Scrip
  2. >>Business

Lexicon Cuts Commercial Operation, Focuses On R&D After FDA Letdown

Pipeline Includes Neuropathic Pain, Cardiomyopathy, Obesity

 
• By Mandy Jackson

With a US FDA determination that sotagliflozin cannot be approved for type 1 diabetes at this time, Lexicon is shutting down its commercial organization to focus on its R&D pipeline.

Lexicon's restructuring plan represents its second round of layoffs this year. (Shutterstock)

Lexicon Pharmaceuticals has not completely given up on sotagliflozin after the US Food and Drug Administration issued a “deficiencies preclude discussion” letter regarding the new drug application (NDA) seeking approval to treat adults with type 1 diabetes and chronic kidney disease (CKD). However, Lexicon said on 22 November that it will restructure, shuttering its commercial organization and ending promotion of sotagliflozin in its approved heart failure indication.

Key Takeaways
  • The US FDA said there were deficiencies in Lexicon’s NDA for Zynquista (sotagliflozin) as a treatment for type 1 diabetes patients with CKD that preclude...

The Woodlands, TX-based Lexicon received notification from the FDA that there were deficiencies in the NDA for Zynquista (sotagliflozin) as an adjunct to insulin in type 1 diabetes patients with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Scrip

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.